{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-327268","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.199239+00:00","generated_at":"2026-06-28T09:13:08.107078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atea reports Q3 net loss $28.2M; plans Phase 3 MORNINGSKY amendment with new primary endpoint","bullets":["Net loss $28.2M for Q3 2021 vs $17.6M loss in Q3 2020; collaboration revenue $32.8M from Roche license.","Cash and equivalents $839.7M as of Sept 30, 2021, down from $850.1M at Dec 31, 2020.","Phase 3 MORNINGSKY amendment: primary endpoint to hospitalization/death; focus on unvaccinated high-risk; dose increased to 1,100 mg BID; data H2 2022.","New infectious virus data from Phase 2 MOONSONG show rapid viral load reduction (-0.5 log10) with AT-527 1,100 mg BID vs placebo at Day 3 in overall population.","In vitro data show AT-511 (free base of AT-527) maintains potency against variants including Delta."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-327268","json":"https://secwatch.observer/filing/0001193125-21-327268.json","markdown":"https://secwatch.observer/filing/0001193125-21-327268.md","text":"https://secwatch.observer/filing/0001193125-21-327268.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312521327268/0001193125-21-327268-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312521327268/d249281d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:13:08.107078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}